There is a growing body of evidence that links epigenetic modifications to type 2 diabetes.
Researchers have more recently investigated effects of commonly used medications, including those prescribed for diabetes, on epigenetic processes. This work reviews the influence of the widely used antidiabetic drug metformin on epigenomics, microRNA levels and subsequent gene expression, and potential clinical implications. Metformin may influence the activity of numerous epigenetic modifying enzymes, mostly by modulating the activation of AMPactivated protein kinase (AMPK). Activated AMPK can phosphorylate numerous substrates, including epigenetic enzymes such as histone acetyltransferases (HATs), class II histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), usually resulting in their inhibition; however, HAT1 activity may be increased. Metformin has also been reported to decrease expression of multiple histone methyltransferases, to increase the activity of the class III HDAC SIRT1 and to decrease the influence of DNMT inhibitors. There is evidence that these alterations influence the epigenome and gene expression, and may contribute to the antidiabetic properties of metformin and, potentially, may protect against cancer, cardiovascular disease, cognitive decline and aging. The expression levels of numerous microRNAs are also reportedly influenced by metformin treatment and may confer antidiabetic and anticancer activities. However, as the reported effects of metformin on epigenetic enzymes act to both increase and decrease histone acetylation, histone and DNA methylation, and gene expression, a significant degree of uncertainty exists concerning the overall effect of metformin on the epigenome, on gene expression, and on the subsequent effect on the health of metformin users.
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| INTRODUCTION
Epigenetics is a rapidly growing field in medical research. Epigenetic modifications, changes to DNA structure that alter gene expression without altering the base nucleotide code, are crucial in the development of organisms and the differentiation and function of specific cell types. For example, epigenetic modifications permit the expression of the insulin gene in pancreatic β cells, while silencing it in other cells. 1 However, epigenetic changes have also been associated with numerous disorders, including type 2 diabetes (T2D), CVD and cancer. 2, 3 Epigenetic processes can be altered by environmental factors including diet, exercise and exposure to toxins, with the foetal environment playing a particularly important role in influencing epigenetic modifications that impact metabolism in adult life; both maternal nutrient deficiency and maternal obesity have been linked to epigenetic changes and the development of T2D in offspring. 4 There is growing evidence that pharmaceuticals also alter epigenetic processes which may contribute to the beneficial and deleterious effects of widelyused medications. 5 As a result of the morbidities and growing prevalence of T2D, the use of medications designed to lower blood glucose is widespread and growing. The biguanide drug metformin is the most widely prescribed antidiabetic drug and is considered the gold standard for treatment of T2D. 6 In 2012, over 60 million prescriptions for metformin were filled in the USA, an increase of 97% from 2003. 7 Therefore, any epigenetic effects of metformin may affect the health of a significant number of individuals. Furthermore, as metformin can be used treat gestational diabetes, this may alter the foetal environment and thus affect the health of offspring. This review explores the epigenetic effects of metformin, including how they may modulate its glucose-lowering and off-target activity, including potential protection from cardiovascular disease, cancer, cognitive decline and aging.
| EPIGENETIC MODIFICATIONS
Epigenetic modifications fall under 2 main categories: histone modifications and DNA methylation. Although they do not interact directly with DNA, microRNAs are also often included as having epigeneticlike effects as they alter protein expression through the suppression of mRNA translation.
| Histone modifications
DNA is wrapped around histone cores composed of 2 each of histone proteins H2A, H2B, H3 and H4; this structure is termed a nucleosome and comprises the fundamental unit of chromatin. DNA can be loosely packed and amenable to transcription as in euchromatin, or highly condensed and silenced as in heterochromatin, the state of organisation being determined by post-translational modifications to histone amino-terminal tails, most notably acetylation, phosphorylation and methylation.
Acetylation of histone lysine residues, particularly of H3 and H4, neutralizes their positive charge and subsequently promotes an open chromatin structure. 8 Histone hyperacetylation is thus considered a signature of active transcription. Histone acetylation is highly dynamic and is regulated by 2 opposing families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs add acetyl groups to lysine residues, using acetyl-CoA as a cofactor.
Of the 2 classes of HATs, Type-A HATs, including the CBP/p300
family, modify multiple sites in histone tails and act as transcriptional co-activators, whereas Type-B HATs, including HAT1, are cytoplasmic and acetylate newly formed histone proteins, but not those already complexed to DNA. 8 HDACs are divided into 4 classes; class I HDACs, including HDAC 1, 2, 3 and 8, are nucleic, whereas class II HDACs, including HDAC 4, 5, 6, 7, 9 and 10, move between the nucleus and cytoplasm. 9 Class III HDACs, also known as sirtuins,
include SIRTs 1 to 7, and are associated with longevity and a decrease in disorders of aging, including T2D. 10 HDAC11 is the only class IV HDAC, of which little is known. Unlike class I, II and IV HDACs, which are zinc dependent, sirtuins rely on NAD+ for their deacetylating activity.
Similar to acetylation, histone phosphorylation neutralizes the positive charge of the histone. 8 Serine, threonine and tyrosine residues serve as the phosphorylation/dephosphorylation sites for protein kinases and phosphatases, respectively, in a process considered important for transcription, and therefore gene expression, as well as for DNA repair, mitosis and apoptosis. DNMT3a and DNMT3b are the de novo methyltransferases; they establish methylation in previously unmethylated cytosines, whereas DNMT1 maintains a state of methylation, for example, in daughter cells following replication. 17 The recently described DNMT3c has been reported to silence retrotransposons in the germ cells of male mice. and the degradation of target mRNAs through the recruitment of deadenylating and decapping enzymes, followed by nucleases. 19 
| METFORMIN
Metformin reduces hyperglycaemia by decreasing hepatic gluconeogenesis and increasing insulin sensitivity. 20 It is also used in the treatment of polycystic ovary syndrome (PCOS) to induce ovulation and regulate menstruation, 21 and it may have additional benefits, as meta-analyses have reported a reduced risk of cardiovascular mortality 22 and cancer 23 in individuals undergoing metformin therapy. Metformin may also be neuroprotective, with placebo-controlled randomized clinical trials reporting that metformin improves cognitive function in the cognitively impaired, such as those with Alzheimer's disease. 24, 25 Metformin was also suggested as an antiaging drug as early as the 1970s, 26 and is currently being investigated in randomized controlled trials, for example, the Targeting Aging with Metformin (TAME) trial. 27 Metformin is generally well tolerated, with gastrointestinal disturbances, particularly diarrhoea, being the most common side effect; less frequently, liver damage and lactic acidosis have also been reported. 28 While the exact mechanisms of action are not completely understood, metformin's ability to promote the phosphorylation and, hence, the activation of AMP-activated protein kinase (AMPK) is considered to be central to its mode of action and to result in the inhibition of gluconeogenic genes. 20 Activation of AMPK, considered a major regulator of cellular metabolism, also impacts numerous pathways, not only those involved in glucose metabolism but also lipid metabolism, mitochondrial biogenesis, autophagy, cell growth and circadian rhythm. 29 There is emerging evidence that metformin-induced modulation of AMPK activity influences epigenetic processes. Given metformin's widespread use, including in gestational diabetes and PCOS, this may be of concern. Studies exploring the effect of maternal metformin treatment on offspring have been limited to short-term studies, and therefore the outcome regarding long-term metabolic effects is not yet known. Follow-up of the Metformin in Gestational diabetes (MiG) trial found that offspring exposed to metformin prenatally had a preferable pattern of fat distribution at 2 years of age, 30 while a Finnish study found that children exposed to metformin and supplemental insulin in utero were heavier at 18 months than children exposed to insulin alone. 31 Similarly, a trial concerning metformin use for PCOS during pregnancy found that infants whose mothers used metformin were heavier at 1 year of age. 32 Animal studies report mixed results, with 1 study by Salomaki et al 33 reporting increased weight gain and impaired glucose tolerance in mice on a high fat diet (HFD) who were exposed to metformin in utero, and a later study by the same group finding that prenatal metformin exposure protected mice from HFDinduced weight gain and impaired glucose tolerance. 34 
| Metformin and epigenetic aging
While the clinical effects of metformin as a pharmacological intervention to promote healthy aging and longevity are currently being investigated in clinical trials, 27, 35 few studies have attempted to do so in the context of epigenetics. Epigenetic markers of aging accumulate with hyperglycaemia, hyperinsulinaemia and metabolic syndrome, 36, 37 and correction of these metabolic abnormalities with metformin may ameliorate epigenetic aging. Metformin may also influence epigenetic aging through interaction with epigenetic modifying enzymes such as SIRT1, the HDAC associated with longevity. The clinical effects of metformin are similar to those of calorie restriction, an intervention known to prolong life, 37 and there is a growing body of evidence that SIRT1 plays an important role in mediating the anti-aging effects of calorie restriction, including antidiabetic actions. 10 In a randomized controlled trial, use of metformin for 2 months altered levels of several effectors associated with longevity, including increased SIRT1 expression in peripheral blood mononuclear cells. 35 In a recent observational study by Quach et al, 36 the degree of DNA methylation in peripheral blood, the "epigenetic clock," was used to assess the effect of a variety of lifestyle factors on the rate of epigenetic aging, known as epigenetic age acceleration. Metformin did not significantly alter extrinsic or intrinsic epigenetic age acceleration, although several other dietary and behavioural factors did. However, while epigenetic age acceleration has been found to correlate closely with expected longevity, it has not been validated as a means of assessing specific pharmacological effects, but rather, is considered to reflect the "cumulative effect of an epigenetic maintenance system." 38 Furthermore, as pointed out by the authors, lack of power and the observational design of this study may mask a real effect, and randomized controlled trials may provide a more convincing result.
| Metformin and histone modifications
Metformin-induced activation of AMPK has been reported to impact histone modifications via multiple mechanisms, including modifications that both increase and decrease gene expression ( Figure 1 ). This includes phosphorylation of HATs, increased SIRT1 activity, inhibition of class II HDACs and, potentially, phosphorylation of histone residues. There is also evidence that metformin may influence HAT expression through AMPK-independent mechanisms, and inhibit HMT expression and histone ubiquitination.
| HATs
The Similarly, metformin-induced AMPK activation results in p300 phosphorylation at Ser89, decreasing its enzymatic activity. 42 AMPKmediated p300 phosphorylation was found to reduce its interaction with nuclear receptors including PPARγ 43 and, consequently, may reduce the transcription of PPARγ target genes, including genes involved in lipid and glucose metabolism. As PPARγ is considered beneficial in T2D, with PPARγ agonists such as thiazolidinediones prescribed as insulin-sensitising agents, it is unclear how this influences the effects of metformin on glucose metabolism.
AMPK may also promote the proteasomal degradation of p300.
Lim et al 41 demonstrated that metformin and AICAR, an unrelated AMPK agonist, reduced p300 protein levels, but not mRNA levels, in hepatic stellate cells, and proteasome inhibition restored protein levels.
Metformin also increased mRNA and protein levels of Gcn5, a type A HAT, in diabetic mice and in a hepatocyte cell line. 44 However, this was not influenced by an AMPK inhibitor, suggesting that metformin alters Gcn5 expression through an unknown, AMPKindependent mechanism. Ser259 and Ser498, 47 and that such phosphorylation of HDAC5 results in its export from the nucleus and, subsequently, to derepression of target genes. 48 This may contribute to the antidiabetic activity of metformin; a previous study reported that AMPK activation decreased HDAC5 association with the glucose transporter type 4 (GLUT4) gene, resulting in increased GLUT4 expression in human primary myotubes, and suggesting a direct mechanism by which metformin could ameliorate insulin resistance in muscle cells. 49 As opposed to the inhibitory effect on class II HDACs, AMPK activation increases SIRT1 activity. 44 This is thought to be a result of NAD+ generation, as both metformin and overexpression of a constitutively active AMPK were reported to increase the NAD+/NADH ratio in myotubes. 50 Metformin may also increase SIRT1 gene expression; in a randomized controlled trial, 2 months of metformin treatment increased SIRT1 mRNA and protein levels in peripheral blood mononuclear cells, although no increase in SIRT1 deacetylase activity was detected. 35 Effects may differ in cancer cells, where metformin has been shown to reduce SIRT1 protein expression. 51 This is mediated through effects on miR-34a, as discussed in a later section.
| HDACs
In animal models, increased SIRT1 activity with use of metformin has been associated with inhibition of gluconeogenesis in the liver, There is also evidence that metformin may reduce cellular aging and improve cardiovascular health through SIRT1, in particular by protecting vascular endothelial cells from cellular stress. In human umbilical vascular endothelial cells, treatment with metformin increased SIRT1 expression and activity and reduced signs of cellular aging and production of reactive oxygen species. 52 These effects were prevented when AMPK was silenced by siRNA. Similarly, Postulated mechanisms by which metformin may modify histones via AMPK activation. Metformin phosphorylates (P) and activates AMPK, which subsequently has been found to activate gene expression through phosphorylation and inactivation of HDACs and activation of HAT1, leading to increased acetylation (Ac) of histone (H) tails. AMPK may also increase gene expression through phosphorylation of histone H2B. Conversely, AMPK may also suppress gene transcription via increasing cellular NAD+ levels, thus increasing SIRT1 deacetylation activity, and via phosphorylation and inactivation of HATs p300 and CBP
Arunachalam et al 53 found that metformin increased SIRT1 expression and conferred protective effects in cultured mouse microvascular endothelial cells exposed to high glucose, including increased levels of the anti-apoptotic Bcl-2 protein and reduced cellular senescence. Silencing SIRT1 prevented these protective effects.
SIRT1 has also been associated with neuroprotection in cellbased and animal models of aging and T2D, and controlled clinical trials with resveratrol, a SIRT1 activator, have shown improved cognitive function. 54 In mice on a high-fat diet, metformin increased hippocampal SIRT1 gene expression. 55 Although this study did not find significant changes in memory or learning with metformin treatment, this mechanism could potentially contribute to the reported neuroprotective effects of metformin.
| Histone methylation
There is evidence that metformin can influence the methylation of numerous histone lysine residues. While both increases and decreases in lysine methylation have been reported, all these modifications are consistent with an increase in gene expression, following from the previously mentioned fact that methylation of lysine residues can either activate (H3K4, H3K36) or repress (H3K9, H3K27)
transcription. In particular, as these studies were conducted using cancer cells to investigate the potential anticancer activity of metformin, changes in histone methylation as a result of metformin treatment may lead to increased expression of tumour suppressor genes.
For example, Banerjee et al 46 reported that metformin treatment decreased H3K9 and H3K27 methylation, and it increased H3K4 methylation in breast cancer cells as well, both globally and specifically at the promoter of the tumour suppressor gene E-cadherin.
These modifications may be a result of inhibition of HMTs; reductions in mRNA and protein expression of SUV39H1 56 and MMSET, 57 HMTs that influence the methylation of H3K9 and H3K27, respectively, have been reported in metformin-treated prostate cancer cells.
The mechanism by which metformin may inhibit HMTs is unknown, as these studies did not examine whether AMPK is directly responsible for the reported effects.
Conversely, 1 study has reported that AMPK can increase histone demethylase activity, although this study did not use metformin treatment. Tanaka 
| Other histone modifications
The direct influence of metformin on histone phosphorylation has not been studied; however, Bungard et al 59 Reduced DNA methylation with metformin treatment has been reported at the insulin gene promoter in a β cell line cultured using high glucose concentrations 65 and at the promoter of the tumour suppressor gene E-cadherin in both cancer cell lines and white blood cells from diabetic patients, 46 leading to increased expression of the respective genes. These results thus implicate DNA demethylation in the antidiabetic and potential anti-cancer actions of metformin. Additionally, reduced methylation of transporter genes SLC22A1, SLC22A3
and SLC47A1, all involved in hepatic transport of metformin, was observed in the livers of diabetic patients receiving metformin but not in the patients who did not receive any antidiabetic medication. 66 Interestingly, these changes were not apparent in patients receiving metformin plus insulin. These changes in methylation may be a result of reduced DNMT activity; activation of AMPK by metformin has been reported to phosphorylate DNMT1 at Ser730 and, consequently, to inhibit its methyltransferase activity. 39 This was associ- 
| Metformin and microRNAs
Metformin has been reported to alter the expression of numerous miRNAs. Alterations in miRNA expression by metformin may be explained, in part, by an increase in DICER, 1 of the key enzymes in miRNA processing. Increases in DICER protein levels have been reported in metformin-treated diabetic humans and mice, 70 and in cancer cells. 71 This increase was also reported in cells treated with AICAR, suggesting AMPK activation as a mechanism. 71 
| Metformin-altered miRNAs in cancer
The potential anti-cancer properties of metformin have been linked to the regulation of numerous miRNAs (see Table 1 ). MiRNAs that may be important in the potential anti-cancer activity of metformin include upregulation of the let-7 family, miR-26a and miR-34a and downregulation of miR-181a, miR-221 and miR-222. Let-7 miRNAs are downregulated in many cancers and target mRNA of oncogenes including Ras and c-Myc, 76 while also inhibiting expression of the SAHH inhibitor H19 and thus impacting DNA methylation (see previous section). 64 MiR-26a is also downregulated in many tumours and has been found to inhibit proliferation and induce apoptosis through the suppression of a number of oncogenes including EZH2, Oct4 and Notch-1. 80 MiR-34a is a transcriptional target of the tumour suppressor p53 and inhibits a number of oncogenes including c-Myc, c-MET and Notch, in addition to the anti-apoptotic Bcl-2 and the HDAC SIRT1. 88 The oncogenic miR-181a induces and maintains stem cell Although overexpression of let-7 has been associated with reduced insulin secretion and insulin sensitivity in mice, 90 a recent study by
Brennan et al 91 suggests that let-7 miRNAs may protect against inflammation in diabetic atherosclerotic plaques. Additionally, the internal mammary arteries of diabetic patients using metformin were found to have lower levels of miR-221 and miR-222 compared to diabetic patients not using metformin. 92 (plasma urea and creatinine) in healthy subjects. 98 In this study, 3 months of metformin treatment increased plasma miR-192 concentration in diabetic patients by nearly 50%; however, whether this resulted in a mitigation of nephropathy was not investigated.
| LIMITATIONS OF STUDIES
The majority of studies reporting epigenetic effects of metformin have been conducted using mouse models or cell culture, with a few exceptions involving human metformin users (increased SIRT1 expression, 35 DNA hypomethylation of certain genes 46, 66 and changes in miRNA expression). 89, 98 There are major limitations to these approaches because of the differences in physiology between mice and humans, and between transformed cell lines in vitro and This may account for some of the disparate results. For example, studies reporting DNA hypomethylation with metformin were conducted in diabetic patients using therapeutic doses of metformin 46, 66 or micromolar doses of 500 μM 65 or 20 μM. 67 Conversely, studies associating metformin with DNA hypermethylation used suprapharmacological concentrations between 1 and 10 mM. 64, 68, 69 For a summary of published studies, including the metformin dose and the model used, see Table S1 online.
Additionally, the reported studies have largely investigated epigenetics in the context of potential beneficial effects of metformin, namely for diabetes, cancer, atherosclerosis, cognitive function and aging, and have not investigated whether these epigenetic modifications could have detrimental side effects. Finally, it is yet to be reported whether use of metformin during pregnancy, in conditions such as gestational diabetes or PCOS, may imprint epigenetic signatures onto the offspring that may programme long-term metabolic changes.
| CONCLUSION
Epigenetics is a rapidly growing field that has been linked with numerous disorders, including T2D. The widely used antidiabetic drug metformin can reportedly modulate numerous epigenetic processes that may contribute to its primary hypoglycaemic action, but may also result in off-target effects, both beneficial and potentially deleterious.
Metformin can alter the activity of many different epigeneticmodifying enzymes, primarily through the phosphorylating actions of AMPK. However, these include modifications that act to both increase and decrease gene expression. Furthermore, the literature suggests that metformin has opposing effects within the major groups of epigenetic-modifying enzymes. Generally, it decreases the activity of most classes of HATs, HDACs and DNMTs through AMPK-mediated phosphorylation and, at the same time, reportedly increases HAT1 and SIRT1 activity and decreases the influence of DNMT inhibitors. This, together with the previously mentioned limitations of published studies, means that it is difficult to make generalizations regarding the effects of metformin on the epigenome, on subsequent gene expression and the type of impact this may have on the health of the millions of metformin users worldwide.
